Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs METAHYDRIN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral vascular resistance via relaxation of vascular smooth muscle, possibly by interfering with calcium transport. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
Essential hypertension (fixed-dose combination for patients who require multiple drugs)
Hypertension,Edema associated with congestive heart failure, hepatic cirrhosis, renal dysfunction, or corticosteroid/estrogen therapy
Initially one capsule (25 mg hydralazine/25 mg hydrochlorothiazide, or 50 mg hydralazine/50 mg hydrochlorothiazide) twice daily, increase as needed to a maximum of 200 mg hydralazine/200 mg hydrochlorothiazide daily.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
Hydralazine: 2-8 hours (terminal, prolonged in renal impairment; acetylator phenotype affects clearance; slow acetylators have 2-fold longer half-life). Hydrochlorothiazide: 6-15 hours (terminal, prolonged in renal impairment; clinically relevant for once-daily dosing).
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Withhold if GFR <30 m L/min. For GFR 30-50 m L/min, reduce dose by 50% or extend interval. Hydrochlorothiazide is ineffective when Cr Cl <30 m L/min.
GFR 30-<60 m L/min: 50 mg once daily. GFR <30 m L/min: 25 mg once daily or every other day.
None
First trimester: Limited human data; animal studies with hydralazine show no consistent teratogenicity, but high doses in rodents have been associated with skeletal anomalies. Hydrochlorothiazide is generally considered low risk, but may cause fetal electrolyte disturbances. Second/third trimester: Hydralazine is used for hypertension; risk of placental hypoperfusion with hypotension. Hydrochlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte imbalance. Avoid in pregnancy-induced hypertension due to decreased placental perfusion.
First trimester: Thiazide diuretics are generally avoided due to potential teratogenic effects, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Associated with fetal or neonatal jaundice, thrombocytopenia, electrolyte imbalances, and possibly hypoglycemia. May cause decreased placental perfusion.
Monitor for lupus-like syndrome (arthralgias, rash, fever) with hydralazine, especially in slow acetylators and doses >200 mg/day. Hydrochlorothiazide may cause hypokalemia, which can be exacerbated by hydralazine-induced reflex tachycardia. Check electrolytes and renal function at baseline and periodically. Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min) as thiazides are ineffective. Avoid in patients with coronary artery disease or mitral valve rheumatic heart disease due to reflex sympathetic activation.
Monitor serum potassium and renal function frequently, especially in patients with diabetes or impaired renal function. Avoid use with potassium supplements or potassium-sparing diuretics to prevent hyperkalemia. May cause azotemia and electrolyte imbalances; elderly patients are more susceptible.
No interactions on record
No interactions on record
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE and METAHYDRIN are distinct pharmacological agents. HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE belongs to the Thiazide Diuretic class and is primarily used for Essential hypertension (fixed-dose combination for patients who require multiple drugs). METAHYDRIN belongs to the Thiazide Diuretic class and is primarily used for HypertensionEdema associated with congestive heart failure, hepatic cirrhosis, renal dysfunction, or corticosteroid/estrogen therapy. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE carries a safety status of Category A/B, whereas METAHYDRIN safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hydralazine: Hepatic acetylation (N-acetyltransferase 2, NAT2); Hydrochlorothiazide: Not extensively metabolized, largely excreted unchanged in urine.
Metahydrin is not extensively metabolized; primarily excreted unchanged by the kidneys.
Hydralazine: 90% renal (primarily as metabolites, 10-15% unchanged); Hydrochlorothiazide: >95% renal (unchanged). Biliary/fecal: negligible for both.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Hydralazine: 85-90% (mainly albumin, alpha-1-acid glycoprotein). Hydrochlorothiazide: 40-70% (albumin).
90-95% (bound to albumin and alpha-1-acid glycoprotein)
Hydralazine: 1.6 L/kg (wide distribution, high tissue binding; reflects extensive extravascular distribution). Hydrochlorothiazide: 3-4 L/kg (extensive distribution, accumulates in erythrocytes).
1.5-2.5 L/kg (indicates extensive tissue distribution, binding to vascular smooth muscle)
Hydralazine: 30-50% (oral; extensive first-pass metabolism; bioavailability increased 2-3 fold with food; slow acetylators have higher bioavailability). Hydrochlorothiazide: 65-75% (oral; absorption reduced by food).
Oral: 90-100% (well absorbed, minimal first-pass metabolism)
Contraindicated in severe hepatic impairment. In Child-Pugh A/B, reduce hydralazine dose by 50% and monitor for hypotension.
Child-Pugh A: no adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: avoid use.
Not recommended due to fixed combination; hydralazine: 0.75-3 mg/kg/day PO divided q6h; hydrochlorothiazide: 1-2 mg/kg/day PO divided q12h. Max hydralazine 7.5 mg/kg/day.
Not recommended for pediatric use; safety not established.
Start at lowest dose (25 mg hydralazine/25 mg hydrochlorothiazide) once daily; titrate slowly due to increased risk of hypotension and electrolyte disturbances; monitor renal function.
Start at 25 mg once daily; titrate slowly. Monitor renal function.
No FDA black box warning.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes) or potassium supplements as hydrochlorothiazide can cause hyperkalemia when combined with ACE inhibitors or ARBs but hypokalemia alone. Limit sodium to control blood pressure. Avoid alcohol as it may potentiate hypotension. Grapefruit juice may increase hydralazine absorption; avoid excessive consumption. Magnesium supplements may increase hypotension risk.
Avoid high-potassium foods and salt substitutes containing potassium chloride. Limit alcohol intake as it may increase hypotensive effects and risk of electrolyte disturbances.
Hydralazine is excreted into breast milk in small amounts (M/P ratio not established); unlikely to cause adverse effects in infants. Hydrochlorothiazide is also excreted in breast milk (low concentrations); may suppress lactation and cause electrolyte disturbances in infant. Use with caution; monitor infant for signs of dehydration, electrolyte imbalance.
Thiazides are excreted in breast milk in small amounts. M/P ratio not well-defined for metahydrin. May suppress lactation and cause neonatal electrolyte disturbances. Use generally avoided in nursing mothers.
Pregnancy may increase clearance of hydralazine due to expanded plasma volume; dose adjustment may be needed to maintain therapeutic effect. Hydrochlorothiazide is generally avoided in pregnancy, especially for hypertension, due to reduced plasma volume and potential for uteroplacental insufficiency; if used, monitor for electrolyte disturbances and adjust dose accordingly.
No specific dose adjustments have been established for pregnancy. However, due to potential decreased placental perfusion and maternal hypovolemia, lower doses or alternative agents are preferred. Monitor maternal response and adjust cautiously.
Take this medication exactly as prescribed, usually twice daily with or without food.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Notify your doctor immediately if you experience joint pain, muscle aches, rash, fever, or unexplained bruising (possible lupus-like reaction).,Avoid sudden standing to prevent dizziness from low blood pressure; rise slowly from sitting or lying down.,This medication may increase sensitivity to sun; use sunscreen and protective clothing.,Do not take any other antihypertensives or diuretics unless prescribed by your doctor.,Report symptoms of low potassium (muscle weakness, cramps, irregular heartbeat) or high sugar (excessive thirst, frequent urination).
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Avoid potassium-rich foods (e.g., bananas, oranges, salt substitutes) unless directed by your doctor.,Do not take any other medications, including over-the-counter products, without consulting your healthcare provider.,Report signs of electrolyte imbalance such as muscle cramps, weakness, irregular heartbeat, or unusual fatigue.,This medication may cause dizziness or lightheadedness; avoid driving or operating machinery until you know how it affects you.